India's largest drugmaker Sun Pharmaceutical Industries Ltd announced that it received US Food and Drug Administration’s approval for CEQUA, a drug that treats dry-eye disease.
CEQUA increases tear production in patients who are suffering from keratoconjunctivitis sicca or dry eye disease with its nanomicellar technology.
Dry eye disease, as defined by the National Eye Institute occurs when the quantity and/or quality of tears fails to keep the surface of the eye properly lubricated, causing scratchy sensation.
"The US FDA approval of CEQUA represents a long-awaited dry eye treatment option and is an important milestone in the development of Sun’s Ophthalmics business. CEQUA, with its novel nanomicellar formulation for a proven dry eye medication, delivers a lipophilic molecule in a clear solution form," Abhay Gandhi, chief executive officer, North America, Sun Pharma said.
The company posted a first-quarter profit of Rs 14.06 crore for the three months ended June 30, compared with a loss of Rs 4,250 crore a year earlier.
First Published: IST